Literature DB >> 9453775

[The computerized repeat prescription. The follow-up of drug consumption and of authorized medication cards over the first 3 years].

M D Roselló Farràs1, M González Solanellas, I Pie Barrufet, M J Pérez Lucena, F Sans Lecussan.   

Abstract

OBJECTIVE: To find the characteristics of the quantitative data and their evolution from June 1993 to June 1996 concerning our system of computerised repeat prescriptions (CRP).
DESIGN: A population-based, longitudinal and observational study.
SETTING: Raval Nord Primary Care District, Barcelona. PARTICIPANTS: All the authorized medication cards (AMC) from the first, second and third years, collected in dBASE-IV.
MEASUREMENTS AND MAIN RESULTS: Overall number of AMC, for pensioners and workers, total number of medicines, mean medicines per AMC, mean attendance of patients by days and mean counterfoils per doctor per month. Sex and age in 1996. The overall number of AMC fell from 3,432 to 3,129. Users attended the CRP service every 68.44 days, which did not change. Overall medicines fell from 12,392 to 11,108. Mean medicines per AMC fell from 3.61 to 3.55. Mean counterfoils per doctor per month fell for pensioners from 18.20 to 14.45, and for workers from 2.00 to 1.63.
CONCLUSIONS: There was a steady fall in all the indicators under study. The profile of the user with an AMC is a woman, pensioner, 65 or over, using the CRP service every two months, with 3.5 authorized medicines per year and receiving steadily less prescriptions.

Entities:  

Mesh:

Year:  1997        PMID: 9453775

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  2 in total

1.  [Computer-aided prescribing in Spain].

Authors:  R Azagra Ledesma; A Aguyé Batista
Journal:  Aten Primaria       Date:  2005-05-31       Impact factor: 1.137

2.  [Computer-aided prescribing: from utopia to reality].

Authors:  J Suárez-Varela Ubeda; C Beltrán Calvo; T Molina López; P Navarro Marín
Journal:  Aten Primaria       Date:  2005-05-31       Impact factor: 1.137

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.